Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Coherus BioSciences targets profitability in 2024 with strong product focus

Coherus BioSciences is strategically positioned to achieve profitability in 2024 through revenue growth and cost control. The company's strong product portfolio and focus on user-friendly solutions provide a competitive edge. Challenges include competition and regulatory approvals, while opportunities exist in expanding product approvals and optimizing expenses.

Coherus BioSciences reports robust Q1 results and eyes market expansion

Coherus BioSciences showcased strong financial performance, product advancements, and strategic initiatives during their Q1 2023 Earnings Call, positioning them for future growth.
While facing challenges such as potential competition and pricing uncertainties, the company's strengths in product diversity, patient engagement, and commercial readiness offer a solid foundation for success.
By capitalizing on opportunities like FDA approvals, therapy combinations, and market share goals, Coherus can navigate challenges and drive innovation in the biopharmaceutical market.

Coherus BioSciences posts robust Q2 earnings, eyes market expansion

Coherus BioSciences reported strong Q2 2023 performance with net product revenues of $58.5 million.
The company aims to achieve cash flow positivity in 2024 through expense management and revenue growth.
Focus on offering low-cost alternatives like CIMERLI and expanding market share for key products.
Plans to leverage the successful launches of UDENYCA and Toripalimab for future growth opportunities.

Coherus BioSciences reports strong Q3 revenue growth and profitability focus

Coherus BioSciences showed strong revenue growth and expense management focus for profitability.
Key products like CIMERLI and UDENYCA drove revenue growth in Q3 2023.
Adjusting R&D expenses to align with revenue and focusing on profitability until mid-2024.
Analysts raised questions on pricing dynamics, profitability goals, and pipeline development plans.

Coherus BioSciences reports strong Q4 results and focuses on growth

Coherus BioSciences showcased strong Q4 results, focusing on efficiency and growth in 2024.
The company achieved FDA approvals for key products, with UDENYCA sales showing growth and LOQTORZI gaining traction.
Financials highlighted cost reductions and pipeline progress, with a cautious approach to revenue projections.
Emphasis on controlling expenses, reducing debt, and driving revenues higher while investing in key products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Lags Q3 Earnings and Revenue Estimates

Coherus BioSciences (CHRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Coherus BioSciences (CHRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Coherus BioSciences (CHRS) is Poised to Beat Earnings Estimates Again

Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Coherus BioSciences (CHRS) Moves to Buy: Rationale Behind the Upgrade

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus' management team will host a conference call to discuss financial results and provide a general business update.

Coherus BioSciences to Report Third Quarter Financial Results on November 5th

Coherus develops and markets biosimilar versions of blockbuster biologic products.

Coherus Has A High-Quality Business Model And Good Long-Term Potential

The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?

Coherus BioSciences Keeps Proving Wall Street Wrong

Coherus BioSciences' (CHRS) CEO Denny Lanfear on Q2 2020 Results - Earnings Call Transcript

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Q2 Earnings and Revenues Top Estimates

– Second Quarter UDENYCA® Net Sales of $135.7 Million –    – Net Income of $59.0 Million –    – Non-GAAP Net Income of $68.3 Million –

Coherus BioSciences Reports Second Quarter 2020 Financial Results

REDWOOD CITY, Calif., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020. 

Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Coherus BioSciences (CHRS) Q2 Earnings Expected to Decline

Biogen

Gen Digital Inc

Lexicon Pharmaceuticals

Salarius Pharmaceuticals Inc

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

5 Value Stocks In The Healthcare Sector

REDWOOD CITY, Calif., July  16, 2020  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after market close on Thursday, August 6, 2020. Starting at 4:30 p.m. ET, Coherus’ management team will host a conference call to discuss financial results and provide a general business update. 

Coherus BioSciences to Report Second Quarter Financial Results on August 6th

The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.

Is Coherus BioSciences a Buy?

Deckers Outdoor

Grupo Aeroportuario del Centro Norte

One way to increase the chances of finding high-quality investments is to look for fairly priced stocks of companies that have good financial conditions and are expected to improve their net earnings per share.

3 Stocks Trading at Attractive Valuations

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q1 2020 Results - Earnings Call Transcript

Coherus BioSciences (CHRS) Earnings Expected to Grow: Should You Buy?

Coherus: Branded Biosimilar Strategy, Cash Reserve, Revenue Stream

Coherus Biosciences: Worth The Risks

Precision Biosciences

These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.

Don't Waste Your Money on Penny Stocks, These 2 Stocks Are Better Buys

BioSpecifics Technologies

CBIZ

DHT Holdings

Euronav

Integer Holdings

Gibraltar Industries

Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.

Check These 7 Top-Ranked Stocks With Solid Net Profit Margins

REDWOOD CITY, Calif., April  15, 2020  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.500% convertible senior subordinated notes due 2026 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering

REDWOOD CITY, Calif., April  14, 2020  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior subordinated notes due 2026 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Coherus also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional 30,000,000 principal amount of notes.

Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering

COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020 COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020

News for Coherus BioSciences Stock (CHRS)